Chapter 24

Effects of Resveratrol on Cognitive Functions

Sebastian Huhn1,2 and A. Veronica Witte1,2,    1Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany,    2University of Leipzig, Leipzig, Germany


Resveratrol (RSV) is a naturally occurring polyphenol found in berries, grapes, red wine, and nuts. Based on numerous animal and human studies, it has been suggested as a possible candidate for the treatment of cardiovascular impairments, metabolic dysfunctions, and neurodegenerative diseases. Beyond that, research has started to focus on its influence on cognitive functions and animal studies have described RSV’s beneficial effects on brain structure and function. The first controlled studies in humans reported the beneficial effects of RSV administration with regard to cognitive functions, especially in older populations. Possible underlying mechanisms of RSV range from antioxidant and antiinflammatory actions to the activation of sirtuins and neuroprotective properties. Future studies should now address previous limitations such as flaws in the study design and focus on translating findings from animals to humans and eventually strengthen the hypothesis that RSV could help maintain cognitive health until old age. This chapter summarizes what is known about the effects of RSV on health outcomes with a focus on cognitive functions and possible underlying mechanisms. In addition, we discuss limitations and challenges of previous studies as well as future perspectives in RSV research.


Resveratrol; polyphenols; cognition; memory; dementia; Alzheimer; neuroprotective; hippocampus


The polyphenol resveratrol (RSV) is probably best known for its crucial role in the so-called French paradox. This concept aims to explain the paradoxical epidemiological observation that the French, despite a diet rich in saturated fatty acids, have a relatively low incidence of cardiovascular complications (Catalgol et al., 2012; Kulkarni and Canto, 2015). As integral ingredient of red wine, RSV is among the components of the French diet that are suspected to positively affect coronary health (Catalgol et al., 2012; Kulkarni and Canto, 2015). Furthermore, the moderate consumption of red wine has been linked to lower incidence of age-related neurological disorders, strokes, and cognitive deficits (Bastianetto et al., 2015).

This chapter starts with a brief overview of the sources, pharmacokinetics, and metabolism of RSV to provide the reader with a better understanding of the physiological processes in the context of RSV administration. In the following section, we provide a review of available animal and human studies on the effects of RSV on cognitive functions followed by a discussion of possible underlying mechanisms. The chapter closes with a discussion about the translation and interpretation of these findings in order to put the current research into a wider framework and point out implications for future studies.

Background: Sources and Pharmacokinetics of Resveratrol

The dietary sources of RSV include blueberries, red currants, and peanuts, although red grapes and red wine are the most substantial sources in the human diet (Baur and Sinclair, 2006; Ingram et al., 2006; Smoliga et al., 2011). The naturally occurring variance in concentration depends not only on the specific source but also on environmental factors such as weather and exposure to stressors (Gambini et al., 2015). An extensive overview of the specific polyphenol content in foods is provided in the online database Phenol-Explorer: Database on Polyphenol Content in Foods (for details, see Rothwell et al., 2013). Within plants, RSV acts as a phytoalexin, meaning it is characterized by low molecular weight and is involved in counteracting certain stressors (Gambini et al., 2015). Those stressors include parasites, fungi, ultraviolet radiation, excessive sunlight, and chemical substances (Carrizzo et al., 2013; Gambini et al., 2015).

Human intake of RSV occurs via the consumption of RSV-containing foods or via dietary supplements. In the intestine, RSV is absorbed by passive diffusion or after forming complexes with membrane transporters (Gambini et al., 2015). Absorption rate is supposed to be approximately 75%, which is rather high for a dietary polyphenol, but it also varies between different food items and ways of consumption (Gambini et al., 2015; Pangeni et al., 2014; Vitaglione et al., 2005; Walle, 2011). For example, RSV absorption is lower after a high-fat breakfast compared to after overnight fasting (la Porte, 2010; Robinson et al., 2015; Vaz-da-Silva et al., 2008).

Once RSV reaches the bloodstream, it is present either in free form as glucuronide or as sulfate (Gambini et al., 2015). Usually RSV is quickly metabolized in phase II in the liver or duodenal cells and thus has low bioavailability (Davinelli et al., 2012). Emerging products are sulfates, glucuronides, and as many as five different urinary products (Gambini et al., 2015). This high rate of metabolism could be counteracted by the administration of RSV in combination with other chemicals such as quercetin that inhibit its sulfation and glucuronidation in the liver and duodenal tissue (De Santi et al., 2000; Gambini et al., 2015). However, others could not confirm these effects (la Porte, 2010), so the underlying mechanisms of how quercetin enhances the bioavailability of RSV remains somewhat unclear. The free form of RSV is characterized by a low water solubility, and more than 90% of free RSV binds to plasma lipoproteins (Gambini et al., 2015). Glucuronides and sulfates are either excreted or converted again to free RSV in target organs such as the liver (Gambini et al., 2015; Park and Pezzuto, 2015). Notably, RSV crosses the blood–brain barrier (Davinelli et al., 2012; Turner et al., 2015) and is thought to exert neuroprotective effects within the brain. For example, RSV was found to attenuate neuronal damage caused by a high-fat diet in mice and to protect against apoptotic insults (Chang et al., 2014).

In humans, supplementary RSV intake is considered to be safe and well tolerated up to 5 g per day (Almeida et al., 2009; Anton et al., 2014; Boocock et al., 2007; Brown et al., 2010; Cottart et al., 2014; la Porte, 2010; Patel et al., 2011; Turner et al., 2015). Minor adverse effects appeared at doses higher than 0.5 g RSV per day over long periods, starting from several weeks and up to one year (Cottart et al., 2014). These were described as mainly affecting the abdomen (e.g., flatulence, mild diarrhea) and remaining moderate and reversible (Cottart et al., 2014). Note that all of these observations are based on supplementary RSV products with a high level of purification and lack of contamination (Virmani et al., 2013). Furthermore, interactions with therapeutic products should be addressed in future studies, even though these have been considered to be marginal, to rule out negative consequences of RSV on pharmacotherapy (MacDonald et al., 2009). In addition, future studies should address the effects of RSV derivatives and analogs, as well as the development of methods that could slow down the rapid metabolism of RSV to eventually increase RSV bioavailability (Cottart et al., 2014).

Animal Studies

Using various animal models, previous research investigated the use of RSV on a multitude of diseases and their underlying mechanisms. For example, improved outcomes in cardiovascular diseases and diabetes have been highly investigated and linked with positive effects of RSV not only on inflammation and oxidative stress but also on cancer (e.g., for reviews, see Knutson and Leeuwenburgh, 2008; Kundu and Surh, 2008; Das and Das, 2007).

Considering cognitive functions, a treatment with RSV was associated with improved spatial learning and memory as well as mood proxies in aged rodents (Abraham and Johnson, 2009; Casadesus et al., 2004; Kodali et al., 2015). The animals received RSV by either consuming blueberries or dietary supplements for at least four weeks. Moreover, findings were similar concerning pharmacologically induced learning deficits in rats (Gacar et al., 2011; Yazir et al., 2015) and in diabetic rats (Schmatz et al., 2009).

In addition, these and other studies (Galli et al., 2006; Liu et al., 2014) reported neuroprotective effects of RSV on the hippocampus, a key area involved in memory and spatial navigation in association with the preservation of cognitive functions. This was also accompanied with improvements in the brain’s microvasculature in the RSV-treated rats compared to control animals (Oomen et al., 2009).

Getting closer to humans, the French RESTRIKAL study investigated the effects of RSV and caloric restriction (CR) in nonhuman primates. The study assessed the effect of an 18-month RSV-supplementation in 33 lemurs in comparison to control or CR subjects (Dal-Pan et al., 2011a; Dal-Pan et al., 2011b). RSV supplementation as well as CR led to a significant improvement in working memory, while only RSV treatment significantly enhanced spatial memory performance (Dal-Pan et al., 2011a).

Human Studies

RSV in human studies made its first appearance in the 1990s in context of the French paradox. Afterward many studies reported improved health outcomes regarding cardiovascular diseases in association with RSV intake. However, available data on cardiovascular disease is still in conflict and definite recommendations to the public cannot yet be made (Kakoti et al., 2015; Zordoky et al., 2015).

Since the early studies in the framework of the French paradox, more research was conducted to identify potential beneficial effects of RSV on other leading causes of death such as obesity, diabetes, and cancer. For all of those diseases, the observed findings are promising in animal models, but the data in humans are not consistent enough and too conflicting to draw final conclusions (de Ligt et al., 2015; Scapagnini et al., 2014; Singh et al., 2015). For example, Semba et al. (2014) could not find a positive effect of RSV, measured in urinary samples, on a population-based cohort of 783 community-dwelling older adults (>65 years of age) in Chianti (Italy). They argued that a typical Western diet does not contain enough RSV to affect outcomes such as inflammation, several diseases, and mortality. Data are, however, most convincing in type 2 diabetes research. Here RSV is considered a leading candidate to support conventional pharmacological management (Hausenblas et al., 2015; Szkudelski and Szkudelska, 2015). The improvements of glycemic control and insulin sensitivity after RSV seem especially crucial for positive health outcomes in diabetes (Brasnyo et al., 2011; Szkudelski and Szkudelska, 2015).

Considering neurodegenerative processes and related decreases in cognitive functions, RSV is currently under phase III clinical trials to determine the potential therapeutic usage (Davinelli et al., 2012). Recently, RSV was found to be a safe and well-tolerated substance in populations at risk for Alzheimer’s disease (AD) (Turner et al., 2015). Indeed, over the last few years, evidence from high-quality studies concluded that polyphenols, including RSV, might have a protective role against AD and other neurodegenerative diseases (Davinelli et al., 2012; Pasinetti et al., 2015; Rege et al., 2014; Tellone et al., 2015). Especially in combination with other compounds (e.g., clioquinol), RSV seems to be a candidate in the process of developing new drugs for AD (Mao et al., 2014).

Taken together, previous evidence suggested that RSV exerts numerous positive effects on human health outcomes, especially in diabetes, and including cognitive decline. Many findings observed in animal studies, however, still need to be established in humans. Yet the translation of animal findings to clinical outcomes faces a variety of challenges that need to be tackled (Singh et al., 2015).

One crucially important issue is that human studies on RSV suffer from a wide heterogeneity in study design (Crichton et al., 2013). For example, concerning the sources of RSV, different foods such as red wine and blueberry juice have been investigated as has isolated RSV administration in the form of a dietary supplement. Therefore, it is difficult to compare the actual dosage each participant received. But also within supplementation trials, the dosage varied substantially, e.g., participants of Brasnyo et al. (2011) received 10 mg daily, while others were administered 250 or 500 mg per day (Kennedy et al., 2010). Furthermore, the designs ranged from cross-sectional studies over single-dose experiments to longitudinal studies that incorporated a daily supplementation for several months. However, only a few randomized controlled trials with limited sample sizes are available so far. In addition, the studied outcome measures such as behavioral and neuropsychological tests were considerably different, rendering a comparison between studies difficult. In sum, the heterogeneity in study design and lack of large-scale randomized controlled trials prevent any recommendation for RSV as a supplement in prevention or therapy of any disease, even though most studies provided promising results (reviewed, e.g., in Huhn et al., 2015; Novelle et al., 2015).

RSV and Cognitive Functions

Considering cognitive effects, most studies investigated RSV within food items, but also data from supplementation studies are available. Nurk et al. (2009) investigated the effects of flavonol-rich foods that are also rich in RSV (chocolate, red wine, and tea) on several cognitive outcomes in a cross-sectional study with 2031 participants aged 70–74 from the Hordaland Health Study in Norway. In that study, a diet high in flavonol-rich foods served over the course of one year was measured using a self-reported food frequency questionnaire and was associated with better abilities in several cognitive domains in a dose-dependent manner compared to a nonconsumer group (Nurk et al., 2009). Red wine in particular had the strongest beneficial effect on cognitive test performance (Nurk et al., 2009).

In another study, Krikorian et al. (2010) administered wild blueberry juice every day for 12 weeks to a small sample of nine older adults with early memory changes. They found improved learning and memory performance in comparison with a matched, placebo-controlled sample (Krikorian et al., 2010).

The impact of a proprietary formulation of blueberries as part of a pill-based nutraceutical was investigated by Small et al. (2014) in a double-blind clinical trial with 52 participants aged 65–85 years in comparison to a placebo (N =53). After two months, the intervention group improved significantly on two measures of processing speed, whereas no other cognitive domain (episodic memory, verbal ability, working memory, executive functioning, or complex speed) was affected (Small et al., 2014).

Brickman et al. (2014) used a diet containing high amounts of cocoa-flavonol in comparison to a low cocoa-flavonol diet in a randomized study with 37 healthy 50- to 69-year-old subjects. After three months of intervention, they found that the high cocoa-flavonol group had significantly enhanced hippocampus-associated memory functions (Brickman et al., 2014). Using functional magnetic resonance imaging (fMRI), they further showed this was associated with higher cerebral blood volume in the dentate gyrus, a hippocampal region characterized by lifelong neurogenesis and known to correlate blood volume with task performance (Brickman et al., 2014).

In the studies using isolated RSV supplements, the group around Kennedy et al. (2010) was the first to report the acute effect of RSV on cerebral blood flow after oral administration of a single dose of either 250 or 500 mg of RSV in a placebo-controlled, randomized crossover design. The 22 healthy adults showed a dose-dependent increase in cerebral blood flow measured via near infrared spectroscopy while they performed several cognitive tasks (Kennedy et al., 2010). Wightman and colleagues from the same working group confirmed those findings in two papers (Wightman et al., 2014; Wightman et al., 2015). Notably, in the latter study, Wightman et al. (2015) did not find chronic changes of cerebral blood flow or cognitive effects after four weeks of RSV supplementation (500 mg/day). This might be explained by the young age of (healthy) participants (28–30 years) because ceiling effects could have masked potential benefits on blood flow and cognitive performance or because of the short duration of the intervention, which might have not been long enough to exert positive effects. Interestingly, blood levels of RSV biomarkers in that study suggested that chronic oral administration of RSV lead to cumulative plasma levels in healthy humans (Wightman et al., 2015).

In our own study with 46 healthy but overweight older individuals, a daily intake of 200 mg RSV (in a formula with quercetin) over 26 weeks significantly improved memory performance compared to placebo intake (Witte et al., 2014). In addition, glycated hemoglobin (HbA1c) in peripheral blood was significantly reduced after RSV treatment, and this reduction in HbA1c correlated with higher functional connectivity of the hippocampus as measured using resting-state fMRI in the same subjects. Notably, changes in functional connectivity were found to partially mediate the observed increases in memory, which points to ameliorated glucose metabolism as one underlying mechanism of the positive effects of RSV on cognition (Witte et al., 2014).

In sum, only a few studies on cognitive functions in humans are available, and their results are inconclusive. Still, older populations in particular might benefit from RSV treatment. Little is known about the possible effects in populations already affected by AD or its precursor, mild cognitive impairment.


Postulated mechanisms of RSV range from antioxidant and antiinflammatory effects to neuroprotection and mimicking of CR. RSV seems to act on so many different molecular pathways and binding partners that it was previously called a “promiscuous molecule” (Britton et al., 2015). However, this variety of pathways might also explain the diverse range of conditions in which RSV appears to be beneficial for health (Britton et al., 2015). The following section contains a summary of the most commonly discussed mechanisms and binding partners of RSV to explain its various actions.

Resveratrol and Oxidation

RSV is suggested to possess both direct and indirect antioxidant effects (Spanier et al., 2009). The direct effect is inherent to the chemical structure of RSV—that is, its polyphenolic characteristic. Polyphenols are secondary metabolites of plants and characterized by the chemical structure of hydroxyl groups on aromatic rings (Manach et al., 2004). These aromatic rings are capable of balancing electron inequalities and either act as electron or hydrogen donors to annihilate free radicals (Vlachogianni et al., 2015).

In contrast, the indirect antioxidant effects are more complex because RSV acts on different pathways. RSV downregulates pro-oxidative enzymes (e.g., nicotinamide adenine dinucleotide phosphate, or NADPH), while at the same time it upregulates antioxidant enzymes (e.g., SOD1, Gpx1) (Spanier et al., 2009). This effect might even be multiplied in combination with synergistic antioxidants such as quercetin or rutin (Iacopini et al., 2008; McAnulty et al., 2013). Even though most of the studies are conducted in vitro, some human studies also have rendered supporting evidence (Crichton et al., 2013; Pignatelli et al., 2006).

The antioxidant effects of RSV are especially interesting in the framework of the free radical theory of aging. Here it is stated that reactive oxygen species (ROS) and oxidative stress contribute to the physiological aging process by causing damage to important cellular targets (Liochev, 2013), and they might thereby be associated with cognitive decline (Droge and Schipper, 2007). ROS-associated damages include increased mutation rate, growth inhibition, and changes of the insulin-signaling pathway (Droge and Schipper, 2007; Liochev, 2013). Nevertheless, it is important to keep in mind that ROS not only are harmful but also lead to adaptive processes that are important and beneficial for the organism (Liochev, 2013). Notably, the antioxidant effects of RSV are also important with regard to cognition because a higher level of ROS was seen in animals to be associated with cognitive deficits (Bastianetto et al., 2015; Dumont and Beal, 2011).

Resveratrol and Inflammation

The antiinflammatory effect of RSV is well shown in vitro; for example, several pathways have been proposed that all lead to a lower activity of nuclear factor kappa B (NFκB) (Jimenez-Gomez et al., 2013; Poulsen et al., 2015). In animal studies, those findings and some of the pathways were confirmed and Wang et al. (2013) showed a dose-dependent effect. Despite quite promising in vitro and animal studies, the available clinical trials have yet to report contradictory findings. Thus, antiinflammatory effects of RSV in humans need to be verified in future studies (Poulsen et al., 2015).

Inflammation is important in terms of cognition. Several neurological diseases such as AD are accompanied by inflammatory processes (Wyss-Coray and Rogers, 2012). Even low-grade subclinical inflammation present, for example, in adiposity and being one characteristic of the metabolic syndrome could lead to neurodegeneration (Misiak et al., 2012; Wyss-Coray and Rogers, 2012). Therefore, RSV was discussed as a therapeutic option in inflammation-related neurological disorders (Zhang et al., 2010), yet results should be interpreted with caution due to various limitations in the available studies (Wyss-Coray and Rogers, 2012).

Resveratrol as Calorie Restriction Mimetic

In addition, RSV seems to mimic calorie restriction. CR is a dietary intervention to deliberately reduce total caloric intake while avoiding malnutrition (Baur, 2010). This intervention was found to delay or prevent age-related diseases and to even prolong life span in animal studies (Baur, 2010; Roth and Ingram, 2015; Wood et al., 2004).

RSV seems to mimic CR especially via the activation of sirtuins (Kulkarni and Canto, 2015). Probably the key mediators of CR, sirtuins are nicotinamide adenine dinucleotide (NAD+)-dependent deacetylases and adenosine diphosphate (ADP)–ribosyltransferases and central to the body’s response to diet and exercise (Baur, 2010; Hubbard and Sinclair, 2014). Sirtuins gained a lot of attention after findings that sirtuins in response to CR can extend life span in organisms ranging from yeast, worms, and flies up to mammals and nonhuman primates (Ingram and Roth, 2015; Russo et al., 2014).

In yeast and animals the sirtuin sir2 is involved in the replicative aging process, the alteration of life span and acts as a metabolic sensor capable of adapting gene expression to the cell’s metabolic state (Kulkarni and Canto, 2015). The association of sirtuins with energy homeostasis seems to apply to humans as well (Lagouge et al., 2006).

The human homologue to sir2 is the sirtuin known as silent mating type information regulation 2 homolog 1 (Sirt1), which has received the most research attention in this regard (Hubbard and Sinclair, 2014; Kim et al., 2007). Sirt1 is involved in numerous vital signaling pathways such as in DNA repair, apoptosis, neurogenesis, and glucose–insulin homeostasis (Hubbard and Sinclair, 2014). Notably, negative alterations in neurogenesis and insulin signaling have been linked to deteriorations in cognitive functions (Cholerton et al., 2013; Couillard-Despres et al., 2011; Lazarov and Marr, 2013).

Also, the CR-mimicking effect of RSV could be beneficial for cognitive functions as CR itself was shown to improve memory performance in a sample of 50 healthy elderly subjects after 3 months of intervention (Witte et al., 2009). A more recent study found improved recognition memory in combination with alterations of the hippocampus after a 12-week CR intervention in 19 postmenopausal obese women (Prehn et al., 2016).

Neuroprotective Effects of Resveratrol

Besides the mechanisms already described that also affect cognition and therefore can be considered neuroprotective, RSV might also exert more directly positive effects on brain pathologies. Probably the most investigated pathology with regard to AD is beta-amyloid (Aβ) and tau pathology. Even though separate mechanisms for Aβ and tau have been discussed to cause toxicity within the brain, Aβ formation is supposed to be the crucial step regarding AD pathogenesis and associated with neuronal death (Bastianetto et al., 2015; Ittner and Gotz, 2011). RSV could counteract the formation of Aβ within this pathological pathway either through its antioxidant effects or via activation of sirtuins (Bastianetto et al., 2015; Davinelli et al., 2012).

Using rodent AD models, it was found that administration of RSV decreases Aß levels in the hippocampus (Kim et al., 2007; Zhao et al., 2015). RSV furthermore protected the integrity of the blood–brain barrier and prevented learning impairment (Kim et al., 2007; Zhao et al., 2015). This effect might be linked to the activation of proteasomal degradation of Aβ or the activation of protein kinase C (or both) (Davinelli et al., 2012; Han et al., 2004; Marambaud et al., 2005). Aβ-induced cell death is probably affected by RSV in a dose-dependent manner (Han et al., 2004). Whether RSV directly leads to those effects or an indirect pathway is activated remains to be elucidated (Bastianetto et al., 2015; Karuppagounder et al., 2009; Wang et al., 2014).

Another component of the neuroprotective effects of RSV is the inhibition of processes leading to neuroinflammation, such as the inhibition of cyclooxygenases (COXs) (Bastianetto et al., 2015). COXs are proinflammatory molecules contributing to neuronal cell death (Bastianetto et al., 2015). Another way to counteract neuro-inflammation is to act on the release of proinflammatory factors by acting on the cellular cascade signaling pathways involving NFκB and activator protein 1 (Bastianetto et al., 2015; Wang et al., 2014). Furthermore, it was shown that RSV has the capacity to modulate the expression of neurotrophic factors such as the nerve growth factor. Neurotrophic factors are related to the development and survival of nerve cells during development, as well as functional maintenance and survival of adult neurons (Anastacio et al., 2014). Thus, RSV might promote neuronal survival via the release of neurotrophic factors (Rahvar et al., 2011).

Taken together, these findings underline the hypothesis that RSV might prevent cognitive decline, because it not only exerts neuroprotective effects within the brain but also attenuates cognitive symptoms related to diseases such as AD (Hubbard and Sinclair, 2014).

Resveratrol and Other Possible Mechanisms

Many more possible mechanisms for the impact of RSV on cognition are debated. They involve, for example, the AMP-activated protein kinase, the PI3K/Akt signaling pathway, or estrogen receptors (Kulkarni and Canto, 2015; Simao et al., 2012). (For detailed reviews on mechanisms and RSV binding partners, see Bitterman and Chung, 2015; Britton et al., 2015; Granzotto and Zatta, 2014; Kulkarni and Canto, 2015.)

Limitations and Challenges for Future Studies

RSV administration has led to promising results in animal studies, yet more studies are needed to establish these findings in humans. To allow proper translation from animal models to humans, future work especially address the limitations of previous studies such as flaws in study design and limited sample sizes and tackle challenges such as finding the most appropriate dosage. This might help to draw better conclusions about the impact of RSV on human cognitive functions.

Concerning the administration of RSV, it is important to conduct further studies with isolated RSV and investigate interactions and possible synergistic or antagonistic effects with other agents such as quercetin and piperine (Bigford and Del Rossi, 2014; Johnson et al., 2011; Kakoti et al., 2015; Skroza et al., 2015; Vang, 2015). To improve the in vivo bioavailability of RSV, it is important to get as close to the active dosage used in animal studies as possible to improve the translation of findings (Johnson et al., 2011; Smoliga and Blanchard, 2014). Therefore, one major target for future trials should be the design of novel analogs that are not metabolized as fast as RSV or to increase solubility or half-life in plasma (Granzotto and Zatta, 2014; Pangeni et al., 2014; Rege et al., 2014; Vang, 2015). With regard to cognitive functions, it is especially noteworthy that RSV can be formulated into a muco-adhesive nanocarrier and thus be directly delivered into the brain through the nasal route (Pangeni et al., 2014).

Future animal studies should further address the different mechanisms underlying the effects of RSV to elucidate whether one or several points of action lead to the multitude of biological effects (Vang, 2015). Furthermore, it might be questioned if current animal models—those, e.g., regarding AD—are a good representation of disease-related processes in humans and if useful information can be extracted from using these models or if their use should be discontinued (Franco and Cedazo-Minguez, 2014).

To improve human studies and clinical trials, several variables must be targeted. Among them, sample size generally needs to be increased (Novelle et al., 2015). Within the studies, the large range of dosages makes it difficult to compare results. Also, more accurate tracing studies assessing RSV concentrations and associated metabolites within human plasma, tissue, and organs after RSV treatment would add knowledge about relevant in vivo dosages (Vang, 2015). The combination of novel encapsulation techniques might further help resolve the problem of solubility, stability, and bioavailability in humans (Davidov-Pardo and McClements, 2014). Besides that, it is also noteworthy to define the most accurate and meaningful biomarkers of RSV in human blood and tissues (Franco and Cedazo-Minguez, 2014). Moreover, the time of administration appears to significantly influence results because e.g., Almeida et al. (2009) found morning administration of RSV to have a higher bioavailability.

Future clinical trials should also carefully select the study population under investigation, as selection bias minimizes positive outcomes (Franco and Cedazo-Minguez, 2014; Smoliga et al., 2013). In this context, also the genetic background (including single-nucleotide polymorphisms) and gene expression, along with differences in age, sex, diet, and physical activity should be monitored (Smoliga et al., 2013). Eventually, only large-scale randomized controlled trials and long-term epidemiological studies together with meta-analyses will help to provide definitive answers on the effectiveness of RSV in humans (Smoliga et al., 2013).


After resveratrol first attracted research interest in the context of the French paradox, more studies were employed and found the supposed health benefits to be not only restricted to cardiovascular outcomes but also extended to diabetes, obesity, and even cancer. As our population is turning older and older, it is important to prolong life span as well as add healthy years to the life span (Hubbard and Sinclair, 2014). Therefore, RSV containing foods and red wine in moderate amounts should be recommended as part of a fruit- and vegetable-enriched diet (Carrizzo et al., 2013). Recent research also focused on the effects of RSV on neurodegenerative diseases and cognitive functions. Here the few randomized controlled studies in humans indicate that RSV administration is well tolerated and might enhance cognitive performance in older populations, yet definite conclusions cannot be drawn to date. However, despite all the limitations and considerations for improving future trials, RSV remains a powerful drug candidate with multispectrum therapeutic application that might provide beneficial health outcomes in future trials (Novelle et al., 2015; Pangeni et al., 2014).


1. Abraham J, Johnson RW. Consuming a diet supplemented with resveratrol reduced infection-related neuroinflammation and deficits in working memory in aged mice. Rejuvenation Res. 2009;12:445–453.

2. Almeida L, Vaz-da-Silva M, Falcao A, et al. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res. 2009;53(Suppl 1):S7–15.

3. Anastacio JR, Netto CA, Castro CC, et al. Resveratrol treatment has neuroprotective effects and prevents cognitive impairment after chronic cerebral hypoperfusion. Neurol Res. 2014;36:627–633.

4. Anton SD, Embry C, Marsiske M, et al. Safety and metabolic outcomes of resveratrol supplementation in older adults: results of a twelve-week, placebo-controlled pilot study. Exp Gerontol. 2014;57:181–187.

5. Bastianetto S, Menard C, Quirion R. Neuroprotective action of resveratrol. Biochim Biophys Acta. 2015;1852:1195–1201.

6. Baur JA. Resveratrol, sirtuins, and the promise of a DR mimetic. Mech Ageing Dev. 2010;131:261–269.

7. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5:493–506.

8. Bigford GE, Del Rossi G. Supplemental substances derived from foods as adjunctive therapeutic agents for treatment of neurodegenerative diseases and disorders. Adv Nutr. 2014;5:394–403.

9. Bitterman JL, Chung JH. Metabolic effects of resveratrol: addressing the controversies. Cell Mol Life Sci. 2015;72:1473–1488.

10. Boocock DJ, Faust GE, Patel KR, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev. 2007;16:1246–1252.

11. Brasnyo P, Molnar GA, Mohas M, et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr. 2011;106:383–389.

12. Brickman AM, Khan UA, Provenzano FA, et al. Enhancing dentate gyrus function with dietary flavanols improves cognition in older adults. Nat Neurosci. 2014;17:1798–1803.

13. Britton RG, Kovoor C, Brown K. Direct molecular targets of resveratrol: identifying key interactions to unlock complex mechanisms. Ann N Y Acad Sci. 2015;1348:124–133.

14. Brown VA, Patel KR, Viskaduraki M, et al. Repeat dose study of the cancer chemo-preventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res. 2010;70:9003–9011.

15. Carrizzo A, Forte M, Damato A, et al. Antioxidant effects of resveratrol in cardiovascular, cerebral and metabolic diseases. Food Chem Toxicol. 2013;61:215–226.

16. Casadesus G, Shukitt-Hale B, Stellwagen HM, et al. Modulation of hippocampal plasticity and cognitive behavior by short-term blueberry supplementation in aged rats. Nutr Neurosci. 2004;7:309–316.

17. Catalgol B, Batirel S, Taga Y, Ozer NK. Resveratrol: French paradox revisited. Front Pharmacol. 2012;3:141.

18. Chang H-C, Tai Y-T, Cherng Y-G, et al. Resveratrol attenuates high-fat diet-induced disruption of the blood–brain barrier and protects brain neurons from apoptotic insults. J Agric Food Chem. 2014;62:3466–3475.

19. Cholerton B, Baker LD, Craft S. Insulin, cognition, and dementia. Eur J Pharmacol. 2013;719:170–179.

20. Cottart C-H, Nivet-Antoine V, Beaudeux J-L. Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans. Mol Nutr Food Res. 2014;58:7–21.

21. Couillard-Despres S, Iglseder B, Aigner L. Neurogenesis, cellular plasticity and cognition: the impact of stem cells in the adult and aging brain – a mini-review. Gerontology. 2011;57:559–564.

22. Crichton GE, Bryan J, Murphy KJ. Dietary antioxidants, cognitive function and dementia – a systematic review. Plant Foods Hum Nutr. 2013;68:279–292.

23. Dal-Pan A, Pifferi F, Marchal J, Picq JL, Aujard F, Consortium R. Cognitive performances are selectively enhanced during chronic caloric restriction or resveratrol supplementation in a primate. PLoS One. 2011a;6:e16581.

24. Dal-Pan A, Terrien J, Pifferi F, et al. Caloric restriction or resveratrol supplementation and ageing in a non-human primate: first-year outcome of the RESTRIKAL study in Microcebus murinus. Age (Dordr). 2011b;33:15–31.

25. Das S, Das D. Anti-inflammatory responses of resveratrol. Inflamm Allergy-Drug Targets. 2007;6:168–173.

26. Davidov-Pardo G, McClements DJ. Resveratrol encapsulation: designing delivery systems to overcome solubility, stability and bioavailability issues. Trends Food Sci Technol. 2014;38:88–103.

27. Davinelli S, Sapere N, Zella D, Bracale R, Intrieri M, Scapagnini G. Pleiotropic protective effects of phytochemicals in Alzheimer’s disease. Oxid Med Cell Longev. 2012;2012:386527.

28. de Ligt M, Timmers S, Schrauwen P. Resveratrol and obesity: can resveratrol relieve metabolic disturbances? Biochim Biophys Acta. 2015;1852:1137–1144.

29. De Santi C, Pietrabissa A, Spisni R, Mosca F, Pacifici GM. Sulphation of resveratrol, a natural compound present in wine, and its inhibition by natural flavonoids. Xenobiotica. 2000;30:857–866.

30. Droge W, Schipper HM. Oxidative stress and aberrant signaling in aging and cognitive decline. Aging Cell. 2007;6:361–370.

31. Dumont M, Beal MF. Neuroprotective strategies involving ROS in Alzheimer disease. Free Radic Biol Med. 2011;51:1014–1026.

32. Franco R, Cedazo-Minguez A. Successful therapies for Alzheimer’s disease: why so many in animal models and none in humans? Front Pharmacol. 2014;5:146.

33. Gacar N, Mutlu O, Utkan T, Komsuoglu Celikyurt I, Gocmez SS, Ulak G. Beneficial effects of resveratrol on scopolamine but not mecamylamine induced memory impairment in the passive avoidance and Morris water maze tests in rats. Pharmacol Biochem Behav. 2011;99:316–323.

34. Galli RL, Bielinski DF, Szprengiel A, Shukitt-Hale B, Joseph JA. Blueberry supplemented diet reverses age-related decline in hippocampal HSP70 neuroprotection. Neurobiol Aging. 2006;27:344–350.

35. Gambini J, Inglés M, Olaso G, et al. Properties of resveratrol: in vitroandin vivostudies about metabolism, bioavailability, and biological effects in animal models and humans. Oxid Med Cell Longev. 2015;2015:1–13.

36. Goldberg DM, Yan J, Soleas GJ. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem. 2003;36:79–87.

37. Granzotto A, Zatta P. Resveratrol and Alzheimer’s disease: message in a bottle on red wine and cognition. Front Aging Neurosci. 2014;6:95.

38. Han YS, Zheng WH, Bastianetto S, Chabot JG, Quirion R. Neuroprotective effects of resveratrol against beta-amyloid-induced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C. Br J Pharmacol. 2004;141:997–1005.

39. Hausenblas HA, Schoulda JA, Smoliga JM. Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus-systematic review and meta-analysis. Mol Nutr Food Res. 2015;59:147–159.

40. Hubbard BP, Sinclair DA. Small molecule SIRT1 activators for the treatment of aging and age-related diseases. Trends Pharmacol Sci. 2014;35:146–154.

41. Huhn S, Kharabian Masouleh S, Stumvoll M, Villringer A, Witte AV. Components of a Mediterranean diet and their impact on cognitive functions in aging. Front Aging Neurosci. 2015;7:132.

42. Iacopini P, Baldi M, Storchi P, Sebastiani L. Catechin, epicatechin, quercetin, rutin and resveratrol in red grape: content, in vitro antioxidant activity and interactions. J Food Compos Anal. 2008;21:589–598.

43. Ingram DK, Roth GS. Calorie restriction mimetics: can you have your cake and eat it, too? Ageing Res Rev. 2015;20:46–62.

44. Ingram DK, Zhu M, Mamczarz J, et al. Calorie restriction mimetics: an emerging research field. Aging Cell. 2006;5:97–108.

45. Ittner LM, Gotz J. Amyloid-beta and tau – a toxic pas de deux in Alzheimer’s disease. Nat Rev Neurosci. 2011;12:65–72.

46. Jimenez-Gomez Y, Mattison JA, Pearson KJ, et al. Resveratrol improves adipose insulin signaling and reduces the inflammatory response in adipose tissue of rhesus monkeys on high-fat, high-sugar diet. Cell Metab. 2013;18:533–545.

47. Johnson JJ, Nihal M, Siddiqui IA, et al. Enhancing the bioavailability of resveratrol by combining it with piperine. Mol Nutr Food Res. 2011;55:1169–1176.

48. Kakoti BB, Hernandez-Ontiveros DG, Kataki MS, Shah K, Pathak Y, Panguluri SK. Resveratrol and Omega-3 Fatty acid: its implications in cardiovascular diseases. Front Cardiovasc Med. 2015;2.

49. Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer’s disease. Neurochem Int. 2009;54:111–118.

50. Kennedy DO, Wightman EL, Reay JL, et al. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. Am J Clin Nutr. 2010;91:1590–1597.

51. Kim D, Nguyen MD, Dobbin MM, et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer’s disease and amyotrophic lateral sclerosis. EMBO J. 2007;26:3169–3179.

52. Knutson MD, Leeuwenburgh C. Resveratrol and novel potent activators of SIRT1: effects on aging and age-related diseases. Nutr Rev. 2008;66:591–596.

53. Kodali M, Parihar VK, Hattiangady B, Mishra V, Shuai B, Shetty AK. Resveratrol prevents age-related memory and mood dysfunction with increased hippocampal neurogenesis and microvasculature, and reduced glial activation. Sci Rep. 2015;5:8075.

54. Krikorian R, Shidler MD, Nash TA, et al. Blueberry supplementation improves memory in older adults. J Agric Food Chem. 2010;58:3996–4000.

55. Kulkarni SS, Canto C. The molecular targets of resveratrol. Biochim Biophys Acta. 2015;1852:1114–1123.

56. Kundu JK, Surh YJ. Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett. 2008;269:243–261.

57. Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 2006;127:1109–1122.

58. la Porte C. Steady-state pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin Pharmacokinet. 2010.

59. Lazarov O, Marr RA. Of mice and men: neurogenesis, cognition and Alzheimer’s disease. Front Aging Neurosci. 2013;5:43.

60. Liochev SI. Reactive oxygen species and the free radical theory of aging. Free Radic Biol Med. 2013;60:1–4.

61. Liu D, Zhang Q, Gu J, et al. Resveratrol prevents impaired cognition induced by chronic unpredictable mild stress in rats. Prog Neuropsychopharmacol Biol Psychiatry. 2014;49:21–29.

62. MacDonald L, Foster BC, Akhtar H. Food and therapeutic product interactions - a therapeutic perspective. J Pharm Pharm Sci. 2009;12:367–377.

63. Manach C, Scalbert A, Morand C, Remesy C, Jimenez L. Polyphenols: food sources and bioavailability. Am J Clin Nutr. 2004;79:727–747.

64. Mao F, Yan J, Li J, et al. New multi-target-directed small molecules against Alzheimer’s disease: a combination of resveratrol and clioquinol. Org Biomol Chem. 2014;12:5936–5944.

65. Marambaud P, Zhao H, Davies P. Resveratrol promotes clearance of Alzheimer’s disease amyloid-beta peptides. J Biol Chem. 2005;280:37377–37382.

66. McAnulty LS, Miller LE, Hosick PA, Utter AC, Quindry JC, McAnulty SR. Effect of resveratrol and quercetin supplementation on redox status and inflammation after exercise. Appl Physiol Nutr Metab. 2013;38:760–765.

67. Misiak B, Leszek J, Kiejna A. Metabolic syndrome, mild cognitive impairment and Alzheimer’s disease--the emerging role of systemic low-grade inflammation and adiposity. Brain Res Bull. 2012;89:144–149.

68. Novelle MG, Wahl D, Dieguez C, Bernier M, de Cabo R. Resveratrol supplementation: where are we now and where should we go? Ageing Res Rev. 2015;21:1–15.

69. Nurk E, Refsum H, Drevon CA, et al. Intake of flavonoid-rich wine, tea, and chocolate by elderly men and women is associated with better cognitive test performance. J Nutr. 2009;139:120–127.

70. Oomen CA, Farkas E, Roman V, van der Beek EM, Luiten PG, Meerlo P. Resveratrol preserves cerebrovascular density and cognitive function in aging mice. Front Aging Neurosci. 2009;1:4.

71. Pangeni R, Sahni JK, Ali J, Sharma S, Baboota S. Resveratrol: review on therapeutic potential and recent advances in drug delivery. Exp Opin Drug Deliv. 2014;11:1285–1298.

72. Park EJ, Pezzuto JM. The pharmacology of resveratrol in animals and humans. Biochim Biophys Acta. 2015;1852:1071–1113.

73. Pasinetti GM, Wang J, Ho L, Zhao W, Dubner L. Roles of resveratrol and other grape-derived polyphenols in Alzheimer’s disease prevention and treatment. Biochim Biophys Acta. 2015;1852:1202–1208.

74. Patel KR, Scott E, Brown VA, Gescher AJ, Steward WP, Brown K. Clinical trials of resveratrol. Ann N Y Acad Sci. 2011;1215:161–169.

75. Pignatelli P, Ghiselli A, Buchetti B, et al. Polyphenols synergistically inhibit oxidative stress in subjects given red and white wine. Atherosclerosis. 2006;188:77–83.

76. Poulsen MM, Fjeldborg K, Ornstrup MJ, Kjaer TN, Nohr MK, Pedersen SB. Resveratrol and inflammation: Challenges in translating pre-clinical findings to improved patient outcomes. Biochim Biophys Acta. 2015;1852:1124–1136.

77. Prehn K, Jumpertz von Schwartzenberg R, Mai K, et al. Caloric restriction in older adults-differential effects of weight loss and reduced weight on brain structure and function. Cereb Cortex. 2016.

78. Rahvar M, Nikseresht M, Shafiee SM, et al. Effect of oral resveratrol on the BDNF gene expression in the hippocampus of the rat brain. Neurochem Res. 2011;36:761–765.

79. Rege SD, Geetha T, Griffin GD, Broderick TL, Babu JR. Neuroprotective effects of resveratrol in Alzheimer disease pathology. Front Aging Neurosci. 2014;6:218.

80. Robinson K, Mock C, Liang D. Pre-formulation studies of resveratrol. Drug Dev Ind Pharm. 2015;41:1464–1469.

81. Roth GS, Ingram DK. Calorie Restriction Mimetics: Progress and Potential. Nutrition, Exercise and Epigenetics: Ageing Interventions. 2015;2:211–243.

82. Rothwell JA, Perez-Jimenez J, Neveu V, et al. Phenol-Explorer 3.0: a major update of the Phenol-Explorer database to incorporate data on the effects of food processing on polyphenol content. Database (Oxford) 2013;2013 bat070.

83. Russo M, Sansone L, Polletta L, et al. sirtuins and resveratrol-derived compounds: a model for understanding the beneficial effects of the mediterranean diet. Endocr Metab Immune Disorders-Drug Targets. 2014;14:300–308.

84. Scapagnini G, Davinelli S, Kaneko T, et al. Dose response biology of resveratrol in obesity. J Cell Commun Signal. 2014;8:385–391.

85. Schmatz R, Mazzanti CM, Spanevello R, et al. Resveratrol prevents memory deficits and the increase in acetylcholinesterase activity in streptozotocin-induced diabetic rats. Eur J Pharmacol. 2009;610:42–48.

86. Semba RD, Ferrucci L, Bartali B, et al. Resveratrol levels and all-cause mortality in older community-dwelling adults. JAMA Intern Med. 2014;174:1077–1084.

87. Simao F, Matte A, Pagnussat AS, Netto CA, Salbego CG. Resveratrol prevents CA1 neurons against ischemic injury by parallel modulation of both GSK-3beta and CREB through PI3-K/Akt pathways. Eur J Neurosci. 2012;36:2899–2905.

88. Singh CK, Ndiaye MA, Ahmad N. Resveratrol and cancer: challenges for clinical translation. Biochim Biophys Acta. 2015;1852:1178–1185.

89. Skroza D, Generalić Mekinić I, Svilović S, Šimat V, Katalinić V. Investigation of the potential synergistic effect of resveratrol with other phenolic compounds: a case of binary phenolic mixtures. J Food Compos Anal. 2015;38:13–18.

90. Small BJ, Rawson KS, Martin C, et al. Nutraceutical intervention improves older adults’ cognitive functioning. Rejuvenation Res. 2014;17:27–32.

91. Smoliga J, Blanchard O. Enhancing the delivery of resveratrol in humans: if low bioavailability is the problem, what is the solution? Molecules. 2014;19:17154–17172.

92. Smoliga JM, Baur JA, Hausenblas HA. Resveratrol and health--a comprehensive review of human clinical trials. Mol Nutr Food Res. 2011;55:1129–1141.

93. Smoliga JM, Colombo ES, Campen MJ. A healthier approach to clinical trials evaluating resveratrol for primary prevention of age-related diseases in healthy populations. Aging (Albany NY). 2013;5:495–506.

94. Spanier G, Xu H, Xia N, et al. Resveratrol reduces endothelial oxidative stress by modulating the gene expression of superoxide dismutase 1 (SOD1), glutathione peroxidase 1 (GPx1) and NADPH oxidase subunit (Nox4). J Physiol Pharmacol. 2009;60(Suppl 4):111–116.

95. Szkudelski T, Szkudelska K. Resveratrol and diabetes: from animal to human studies. Biochim Biophys Acta. 2015;1852:1145–1154.

96. Tellone E, Galtieri A, Russo A, Giardina B, Ficarra S. Resveratrol: a focus on several neurodegenerative diseases. Oxid Med Cell Longev. 2015;2015:1–14.

97. Turner RS, Thomas RG, Craft S, et al. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology 2015.

98. Vang O. Resveratrol: challenges in analyzing its biological effects. Ann N Y Acad Sci. 2015;1348:161–170.

99. Vaz-da-Silva M, Loureiro AI, Falcao A, et al. Effect of food on the pharmacokinetic profile of trans-resveratrol. Int J Clin Pharmacol Ther. 2008;46:564–570.

100. Virmani A, Pinto L, Binienda Z, Ali S. Food, nutrigenomics, and neurodegeneration--neuroprotection by what you eat!. Mol Neurobiol. 2013;48:353–362.

101. Vitaglione P, Sforza S, Galaverna G, et al. Bioavailability of trans-resveratrol from red wine in humans. Mol Nutr Food Res. 2005;49:495–504.

102. Vlachogianni IC, Fragopoulou E, Kostakis IK, Antonopoulou S. In vitro assessment of antioxidant activity of tyrosol, resveratrol and their acetylated derivatives. Food Chem. 2015;177:165–173.

103. Walle T. Bioavailability of resveratrol. Ann N Y Acad Sci. 2011;1215:9–15.

104. Wang B, Sun J, Li X, et al. Resveratrol prevents suppression of regulatory T-cell production, oxidative stress, and inflammation of mice prone or resistant to high-fat diet-induced obesity. Nutr Res. 2013;33:971–981.

105. Wang J, Bi W, Cheng A, et al. Targeting multiple pathogenic mechanisms with polyphenols for the treatment of Alzheimer’s disease-experimental approach and therapeutic implications. Front Aging Neurosci. 2014;6:42.

106. Wightman EL, Reay JL, Haskell CF, Williamson G, Dew TP, Kennedy DO. Effects of resveratrol alone or in combination with piperine on cerebral blood flow parameters and cognitive performance in human subjects: a randomised, double-blind, placebo-controlled, cross-over investigation. Br J Nutr. 2014;112:203–213.

107. Wightman EL, Haskell-Ramsay CF, Reay JL, et al. The effects of chronic trans-resveratrol supplementation on aspects of cognitive function, mood, sleep, health and cerebral blood flow in healthy, young humans. Br J Nutr. 2015;114:1427–1437.

108. Witte AV, Fobker M, Gellner R, Knecht S, Floel A. Caloric restriction improves memory in elderly humans. Proc Natl Acad Sci USA. 2009;106:1255–1260.

109. Witte AV, Kerti L, Margulies DS, Floel A. Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults. J Neurosci. 2014;34:7862–7870.

110. Wood JG, Rogina B, Lavu S, et al. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature. 2004;2004:686.

111. Wyss-Coray T, Rogers J. Inflammation in Alzheimer disease - a brief review of the basic science and clinical literature Cold Spring Harb. Perspect Med. 2012;2:a006346.

112. Yazir Y, Utkan T, Gacar N, Aricioglu F. Resveratrol exerts anti-inflammatory and neuroprotective effects to prevent memory deficits in rats exposed to chronic unpredictable mild stress. Physiol Behav. 2015;138:297–304.

113. Zhang F, Liu J, Shi JS. Anti-inflammatory activities of resveratrol in the brain: role of resveratrol in microglial activation. Eur J Pharmacol. 2010;636:1–7.

114. Zhao HF, Li N, Wang Q, Cheng XJ, Li XM, Liu TT. Resveratrol decreases the insoluble Abeta1-42 level in hippocampus and protects the integrity of the blood-brain barrier in AD rats. Neuroscience. 2015;310:641–649.

115. Zordoky BN, Robertson IM, Dyck JR. Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases. Biochim Biophys Acta. 2015;1852:1155–1177.

..................Content has been hidden....................

You can't read the all page of ebook, please click here login for view all page.